Furegrelate sodium

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

呋吉酯钠是一种具有口服活性的选择性血栓素合酶抑制剂。

Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.(In Vivo):Furegrelate sodium has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs) and reportedly is highly specific for its target enzyme. Furegrelate sodium (1-5 mg/kg; oral) prevents blockage of the coronary artery. Furegrelate sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused by platelet aggregation. Furegrelate sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.?

——

Animal Model:Mongrel dogs (19-30 kg)Dosage:1-5 mg/kg Administration:Oral (via a gastric tube)Result:Prevented blockage of the coronary artery.

U-63557A

Metabolic Enzyme/Protease

PPAR

B-Raf (V600E)

——

——

85666-17-7

275.239

C15H10NNaO3

>98% (HPLC)

In Vitro:?DMSO : 13 mg/mL (47.23 mM)

[Na]OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1

——

(-20℃)

With Ice Pack

≥ 2 years